This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
It seems even interventional cardiologists arent immune to the Weekend Effect as a recent study suggests patients admitted on weekends for TAVR procedures face significantly higher risks. The post The Weekend Effect Touches TAVR Too appeared first on Cardiac Wire.
Cardiologists have a wide selection of TAVR valves to choose from, and a new study pitting the top three second generation devices against each other suggests theres not much difference in the long run. So far, we havent known the long-term clinical outcomes of second-generation devices for TAVR beyond five years after implantation.
Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. Evolut TAVR vs. 9.3% Evolut TAVR vs. 9.3% Grubb, M.D., 1 Herrmann H.
(MedPage Today) -- NEW YORK CITY -- Researchers eked out evidence of a small clinical benefit with the Sentinel cerebral embolic protection (CEP) device in transcatheter aortic valve replacement (TAVR) -- and pointed to the patients more likely.
TAVR and SAVR are procedures to replace a damaged aortic valve that is not functioning properly. TAVR and SAVR are procedures to replace a damaged aortic valve that is not functioning properly. The DEDICATE-DZHK6 trial compared TAVR vs. SAVR in 1,414 patients who underwent valve replacement procedures at 38 centers in Germany.
While the numbers increase, still the debate between SAVR and TAVR is riddled with speculation, skepticism, and absolute confidence. Expected to improve with polymer valves) The latest trial to join the litereture is EARLY TAVR in October 2024 Here is a brief, personal comment about the paper for non-academic consumption.
milla1cf Fri, 06/07/2024 - 14:50 June 7, 2024 — Medtronic today announced new data from the CoreValve Evolut Clinical Program , reinforcing the positive performance of the Evolut transcatheter aortic valve replacement (TAVR) System compared to surgical aortic valve replacement (SAVR) and other TAVR valves. Evolut vs. 10.6%
Molham Aldeiri , have successfully performed the first series of transcarotid Transcatheter Aortic Valve Replacement (TAVR) procedures ever done in Southeast Houston. TAVR , whether through the groin approach or neck approach, only requires a half-inch or inch incision.
From a pool of 37,011 patients, the study identified 2,360 patients under the age of 60 years who underwent these procedures, with 22% receiving TAVR and 78% SAVR. By 2021 almost half of patients younger than 60 years were receiving TAVR rather than SAVR. years after TAVR and 4.9 years after TAVR and 4.9
Patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke at five years, according to research presented during a Late-Breaking Clinical Trial session at ACC.25 25 in Chicago and simultaneously published in JACC.
Getty Images milla1cf Wed, 05/15/2024 - 19:10 May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aortic valve in the heart— transcatheter aortic valve replacement (TAVR)—and surgical aortic valve replacement (SAVR). 1.11, p=0.70) with similar long-term mortality risks.
Resource SAVR After TAVR Risk Calculator kchalko Fri, 04/12/2024 - 13:53 SAVR after previous TAVR is the fastest-growing cardiac surgery procedure in the U.S. The majority of patients require explant of their TAVR device and SAVR with significantly increased risk of operative mortality and stroke.
SAVR after TAVR Surgical aortic valve replacement after prior TAVR is the fastest-growing cardiac surgery procedure in the U.S. The majority require explant of the TAVR device and SAVR, which significantly increases the risk of operative mortality and stroke. and 3.8%, respectively.
While the main PROTECTED TAVR trial found no significant differences in stroke rates when cerebral embolic protection (CEP) was used during TAVR compared with TAVR alone, a post hoc analysis of the trial presented during TCT 2024 and simultaneously published in JAMA Cardiology, suggests there may be potential benefits associated with CEP use based (..)
In light of the growing number of patients undergoing transcatheter aortic valve replacement (TAVR), there is an increasing demand for data regarding the management of failed TAVR procedures, including the possibility of a repeat TAVR intervention. vs. 19.0%, p=0.57), as well as stroke at 30 days (2.0% vs. 3.3%, p=0.18).
The SMART trial is the first randomized head-to-head comparison of the two most widely used TAVR devices—the supra-annular self-expanding Evolut PRO/PRO+/FX and the balloon-expandable SAPIEN 3/3 Ultra. The trial enrolled 716 patients who underwent TAVR at 83 international sites in North America, Europe and the Middle East.
What is the relationship between diffusion-weighted magnetic resonance imaging (DW-MRI) total lesion number (TLN), individual lesion volume (ILV), and total lesion volume (TLV) with clinical stroke outcomes after transcatheter aortic valve replacement (TAVR)?
According to the Centers for Disease Control and Prevention (CDC), heart disease and stroke rank as the first and fifth leading causes of death in the nation. About 276,000 patients have undergone a TAVR procedure in the United States.
TAVR was found to bring no increased risks and was associated with substantially decreased rates of death or stroke at one year in low-risk patients, compared with surgical aortic valve replacement (SAVR), according to results from the DEDICATE-DZHK6 study presented during a Late-Breaking Clinical Trial session at ACC.24
A cost-effectiveness analysis demonstrates the positive economic value of transcatheter aortic valve replacement (TAVR) using Evolut TAVR compared to surgical aortic valve replacement (SAVR) for low-risk patients. The findings showed a strong economic benefit of Evolut TAVR for low-risk patients from a U.S.
Among patients with asymptomatic severe aortic stenosis, early TAVR was superior to clinical surveillance in reducing the incidence of death, stroke, or unplanned hospitalization for cardiovascular causes.
In women with symptomatic, severe aortic stenosis (AS), TAVR with the balloon-expandable valve was superior to surgical aortic valve replacement in terms of the composite rate of death, stroke and rehospitalization at one-year follow-up, according to a pooled analysis of patient-level data from RHEIA and PARTNER 3 trials presented at TCT 2024.
Cardiac Surgery after Transcatheter Aortic Valve Replacement: Trends and Outcomes The researchers set out to document trends and outcomes in cardiac surgery following transcatheter aortic valve replacement (TAVR), a topic gaining importance as reports of subsequent cardiac operations and early TAVR explantations increase.
(MedPage Today) -- The woman who received a pig kidney transplant soon after getting a mechanical heart pump has died. New York Times) Skeptics continue to question the safety of the MitraClip after three device recalls and reports of patient.
Multiple Randomized Trials Prove More Stroke Patients Can Benefit from Thrombectomy 4. Atlantic Health System’s Morristown Medical Center Tops 5,000 TAVR Procedures 8. Landmark Clinical Study in The Lancet Finds New AI Technology Can Predict Cardiac Events Due to Coronary Inflammation at Least 10 Years in Advance 3.
The goal of the PROTECTED TAVR trial was to evaluate the efficacy of intraprocedural cerebral embolic protection (CEP) in reducing strokes among patients undergoing transfemoral TAVR for aortic stenosis.
He then examines the temporal trends and clinical implications of ischemic stroke in women with atrial fibrillation. Eagle looks at a scientific statement from the American Heart Association on the diagnosis and management of cardiac sarcoidosis.
BackgroundAcute ischemic stroke complicates 2% to 3% of transcatheter aortic valve replacements (TAVRs). This study aimed to identify the aortic anatomic correlates in patients after TAVR stroke.Methods and ResultsThis is a single‐center, retrospective study of patients who underwent TAVR at the Mayo Clinic between 2012 and 2022.
Seven studies showed that TAVR patients had a similar 1-year stroke risk to SAVR patients (OR 0.92, 95% CI 0.64 In the TIA case, there was no evidence of a significant difference between TAVR and SAVR in the risk of having a transient ischemic attack within 30 days following surgery (OR 0.93, 95% CI 0.24 to 1.17, p=0.30, I2 3%).
Transcarotid transcatheter aortic valve replacement (TC-TAVR) has emerged as an alternative access in suboptimal transfemoral candidates, but no data exist comparing TC-TAVR and SAVR. At 30 days, the SAVR group showed a higher rate of the primary composite outcome compared with the TC-TAVR group (12.6% andP=0.001, respectively).
The EARLY TAVR trial results demonstrate that early transcatheter aortic valve implantation in patients with asymptomatic severe aortic stenosis is superior to clinical surveillance in significantly reducing the composite primary outcome of death, stroke, or unplanned hospitalization for cardiovascular causes.
Transcatheter Mitral Valve Repair is Cost-Effective in Heart Failure Patients TAVR Expected to See Rapid Growth in Next 5 years FDA Clears Abbott Amplatzer Amulet LAA Occluder to Reduce Stroke in People With Atrial Fibrillation Portico TAVR System Found Safe and Effective for High-Risk Surgical Patients Portico TAVR System Reduces Severe (..)
Background: Atrial fibrillation (AF) is common in patients undergoing transcatheter aortic valve replacement (TAVR) and is associated with increased risk of bleeding and stroke. Patients were randomized 1:1 to TAVR+LAAO or TAVR+medical therapy. For the composite primary endpoint, TAVR+.LAAO compared to 50.8%
Objective To evaluate whether transcatheter or surgical aortic valve replacement (TAVR or SAVR) affects clinical and haemodynamic outcomes in symptomatic patients with moderately-severe aortic stenosis (AS). Valve haemodynamics improved following TAVR (AVA 2.5±0.7 <aortic valve area (AVA)<1.5 cm 2 , 3.0<peak
Objective Postprocedural ischaemic and bleeding risks after transcatheter aortic valve replacement (TAVR) remain a major concern. We aimed to assess the accuracy of percutaneous coronary intervention (PCI)-derived models and the performance of a recalibrated model that included variables more applicable to TAVR.
Abstract: Transcatheter aortic valve replacement (TAVR) is an interventional procedure performed in patients with severe aortic stenosis and often required perioperative antiplatelet therapy. Most previous studies have focused on antiplatelet therapy following TAVR.
We performed a pairwise meta-analysis, comparing the efficacy of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in patients with BAV. There were 60,858 patients with BAV (7,565 TAVR, 53,293 SAVR) included. Medical databases were queried to pool comparative studies of interest.
BackgroundValveinvalve transcatheter aortic valve replacement (TAVR) is a recognized alternative for treating the structural valve deterioration of bioprosthetic valves. Recent guidelines and trials have expanded the indications for TAVR to include younger patients with structural valve deterioration.
The objectives of this study were to compare the hemodynamic and clinical outcomes between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with a SAA.Methods:Prospective multicenter international randomized trial performed in 15 university hospitals.
TAVR in heart failure. The use of transcatheter aortic valve replacement (TAVR) has become the preferred therapy for most patients with AS and concomitant HF. The prognostic covariates and optimal timing of TAVR in patients with less than severe AS remain unclear.
Objective To investigate the impact of prior coronary artery bypass grafting (CABG) and coronary lesion complexity on transcatheter aortic valve replacement (TAVR) outcomes for aortic stenosis. Conclusion Prior CABG may positively affect mid-term TAVR outcomes for aortic stenosis compared with no CAD when adjusted for other comorbidities.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content